Concepedia

Publication | Open Access

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

DOIFull Paper Access

11

Citations

31

References

2021

Year

Hiddo J.L. Heerspink, Gordon Law, Konstantina Psachoulia, Kathleen Connolly, Carl Whatling, Hans Ericsson, Jane Knöchel, Eva‐Lotte Lindstedt, Iain MacPhee
Kidney International Reports

Abstract

FLAIR will provide data on the effects of 5-lipoxygenase pathway inhibition in patients with proteinuric CKD with or without type 2 diabetes, and will form the basis for future clinical trials (ClinicalTrials.gov: NCT04492722).

References

YearCitations

Page 1